Related Experiment Video

Updated: Mar 24, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

493

Oncogenic MicroRNAs Biogenesis as a Drug Target: Structure-Activity Relationship Studies on New Aminoglycoside

Duc Duy Vo1, Thi Phuong Anh Tran1, Cathy Staedel2,3

  • 1University of Nice Sophia Antipolis, Institute of Chemistry of Nice, UMR7272 CNRS, Parc Valrose, 06100, Nice, France.

Chemistry (Weinheim an Der Bergstrasse, Germany)
|March 2, 2016
PubMed

Insights

New small-molecule drugs targeting oncogenic microRNAs (miRNAs) show promise for cancer therapy. These compounds inhibit the production of specific miRNAs involved in gastric cancer, reducing cancer cell proliferation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression.
  • Aberrant miRNA expression is linked to various human cancers, including gastric cancer.
  • Targeting oncogenic miRNAs offers a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To synthesize and biologically evaluate novel small-molecule drugs targeting oncogenic miRNA production.
  • To investigate the inhibition of miRNA-372 and miRNA-373, implicated in gastric cancer.
  • To develop new therapeutic leads for cancer by inhibiting oncogenic miRNAs.

Main Methods:

  • Synthesis of novel small-molecule conjugates.
  • In vitro evaluation of Dicer processing inhibition for pre-miRNAs.
  • Assessment of inhibition on adenocarcinoma gastric cancer (AGS) cell proliferation.

Main Results:

  • Newly synthesized conjugates effectively inhibit Dicer processing of targeted pre-miRNAs in vitro.
  • Inhibition efficacy surpasses previous results.
  • Compounds significantly inhibit the proliferation of AGS cells overexpressing target miRNAs.

Conclusions:

  • The developed small-molecule drugs demonstrate potent inhibition of oncogenic miRNA production.
  • These drugs show significant anti-proliferative effects on gastric cancer cells.
  • The findings represent promising advancements for future cancer drug development targeting miRNAs.
Keywords:
RNA structuresbiogenesiscancerinhibitorsmicroRNA

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

841
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.1K

Related Concept Videos

Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
24
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
29
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.2K